Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07758634
PHASE1/PHASE2

A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension

Sponsor: CRISPR Therapeutics AG

View on ClinicalTrials.gov

Summary

A Study of CTX340 in Participants with Uncontrolled Hypertension.

Official title: A Phase 1/2 Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety, Tolerability, and Efficacy of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX340) for In Vivo Editing of the Angiotensinogen (AGT) Gene in Participants With Hypertension

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

69

Start Date

2026-08-08

Completion Date

2029-07-01

Last Updated

2026-08-11

Healthy Volunteers

No

Conditions

Interventions

DRUG

CTX340

CTX340 is an in vivo gene editing therapy designed to utilize clustered regularly interspaced short palindromic repeats-CRISPR-associated protein 9 (CRISPR-Cas9) to target and disrupt human angiotensinogen (AGT) gene in liver.

DRUG

Placebo

One of the arms in Phase 2 will be placebo.

Locations (2)

Research Site 1

Port Orange, Florida, United States

Research Site 2

Melbourne, Australia